Micronutrient Depletion in Perimenopause: Iron, Magnesium and the Thyroid Loop

MARKABLE Research Team · August 2026 · 9 min read

Fatigue, dizziness, palpitations, cognitive slowing and myalgia are attributed to the menopause transition in large numbers of midlife women, frequently without baseline haematinics or thyroid function. In a meaningful proportion, a depleted store sits underneath the hormonal picture, and the two are causally linked rather than merely coincident.

Summary. The common framing that hormone deficiency impairs micronutrient absorption is only partly accurate. For iron and B12 in this population, the dominant mechanism is loss and prior depletion rather than malabsorption. Two mechanistic loops matter clinically: iron deficiency impairs thyroid hormone synthesis through heme dependent thyroid peroxidase, and magnesium is a required cofactor for vitamin D metabolism. This article is educational content for clinicians and informed readers, not clinical guidance.

The mechanism worth stating precisely

It is useful to separate two claims that are often merged.

Bone and calcium. Here the hormonal effect is direct. Prior describes estradiol as preventing rapid bone resorption and progesterone as supporting progesterone receptor mediated osteoblastic bone formation, with the two collaborating to keep bone mineral density stable when cycles are normally ovulatory (Prior, 2018).
Iron and vitamin B12. Here the dominant mechanism is different. Loss and prior depletion, not impaired absorption, account for most of what is seen in perimenopausal women.

The upstream driver is ovulatory disturbance. Prior and Hitchcock describe perimenopause as erratically higher estradiol with decreased progesterone in anovulatory or short luteal phase cycles (Prior & Hitchcock, 2011). Relatively unopposed estrogenic stimulation of the endometrium is a recognised contributor to heavy and unpredictable bleeding, and each such cycle represents iron loss. Where there has been recent pregnancy and lactation, that loss occurs against an already depleted baseline. See our review of the postpartum and perimenopause overlap.

Loop one: iron and the thyroid

Iron deficiency produces fatigue, exertional dyspnoea, palpitations, dizziness and reduced exercise tolerance, which overlaps substantially with vasomotor and autonomic complaints attributed to the transition.

The less widely applied point is the thyroid interaction. Zimmermann and Kohrle state directly that iron deficiency impairs thyroid hormone synthesis by reducing the activity of heme dependent thyroid peroxidase, and further that iron deficiency anaemia blunts, while iron supplementation improves, the efficacy of iodine supplementation (Zimmermann & Kohrle, 2002).

Clinically this means iron status and thyroid function are not alternative hypotheses for the same presentation. One can generate the other, and both should be measured.

On measurement: haemoglobin may remain within reference range while storage iron is depleted. Ferritin falls earlier and should be requested explicitly rather than inferred from a normal full blood count, with the caveat that ferritin rises as an acute phase reactant.

Loop two: magnesium and vitamin D

Magnesium contributes to cardiac electrical activity, neuromuscular function and sleep architecture, so inadequacy presents as cramping, palpitations, hyperarousal and fragmented sleep, again overlapping closely with the transition.

Uwitonze and Razzaque review the interdependence and report that all of the enzymes that metabolise vitamin D appear to require magnesium as a cofactor in the enzymatic reactions in the liver and kidneys (Uwitonze & Razzaque, 2018). Where magnesium status is inadequate, vitamin D repletion may therefore underperform, and assessing the pair together is more informative than either in isolation.

Vitamin B12 and the cognitive presentation

Low B12 produces fatigue, cognitive slowing and peripheral paraesthesia. Cognitive complaint is among the most frequently reported perimenopausal symptoms and among the most characteristic presentations of B12 deficiency. Risk is elevated after pregnancy and lactation, in plant based diets, and with long term use of certain medications. These are two candidate explanations for an identical complaint, separable only by measurement.

The musculoskeletal overlap

Wright and colleagues introduced the term musculoskeletal syndrome of menopause to describe the collective musculoskeletal signs and symptoms associated with declining estrogen, including arthralgia, loss of muscle mass, loss of bone density and progression of osteoarthritis. They estimate that more than 70 percent of women experience musculoskeletal symptoms through the transition and that 25 percent are disabled by them (Wright et al., 2024).

Because inadequate magnesium, vitamin D and iron produce overlapping myalgia, weakness and cramping, attributing the whole picture to either cause alone is likely to be incomplete.

A reasonable baseline panel

Offered as context for discussion rather than as a protocol. Investigation and interpretation remain matters for the treating clinician.

Ferritin with full blood count
Vitamin B12
25-hydroxyvitamin D
Magnesium and calcium
TSH, free T4 and thyroid peroxidase antibodies

A note on supplementation. Iron should not be initiated without measurement. Excess iron is harmful and hereditary haemochromatosis is not rare in populations of northern European ancestry. Vitamin D and magnesium dosing likewise depend on individual status and concurrent medication.

Framing for the consultation

Correcting a micronutrient deficiency does not address the hormonal transition, and hormonal management does not repair a depleted store. In this population the two commonly coexist and interact. The productive framing is not differential but additive: assess symptom pattern across the cycle alongside baseline bloodwork. For the neurosteroid contribution to the same symptom cluster, see our review of progesterone and allopregnanolone in perimenopause.

Separate the overlapping signals

MARKABLE produces a personal baseline across facial, cognitive, sensory and symptom signals that can be repeated over time, so change is visible alongside laboratory results rather than instead of them.

Schedule a Demo

Frequently Asked Questions

Does the hormonal transition impair micronutrient absorption?

The mechanisms differ by nutrient and the distinction is clinically useful. For calcium and bone, sex steroids act directly on bone turnover. For iron and vitamin B12, the dominant mechanism in this population is loss and prior depletion rather than malabsorption: anovulatory cycles with relatively unopposed estrogen drive menorrhagia and iron loss, and recent pregnancy and lactation deplete stores in advance.

Why does iron deficiency affect thyroid function?

Thyroid peroxidase is a heme dependent enzyme. Zimmermann and Kohrle state that iron deficiency impairs thyroid hormone synthesis by reducing the activity of heme dependent thyroid peroxidase. Iron status and thyroid function should therefore be assessed together rather than treated as competing explanations for the same presentation.

Why should magnesium be considered alongside vitamin D?

Uwitonze and Razzaque report that all of the enzymes that metabolise vitamin D appear to require magnesium as a cofactor in the liver and kidneys. Where magnesium status is inadequate, vitamin D repletion may underperform expectations. Assessing the two together is more informative than either alone.

Is a normal haemoglobin sufficient to exclude iron deficiency?

No. Haemoglobin can remain within reference range while iron stores are depleted. Ferritin reflects storage iron and falls earlier, so it should be requested explicitly. Ferritin is an acute phase reactant and can be elevated by inflammation, so interpretation requires clinical context.

How does this interact with musculoskeletal symptoms?

Wright and colleagues introduced the term musculoskeletal syndrome of menopause to describe arthralgia, loss of muscle mass, declining bone density and osteoarthritis progression across the transition, estimating that more than 70 percent of women experience musculoskeletal symptoms and 25 percent are disabled by them. Because low magnesium, vitamin D and iron produce overlapping symptoms, both the hormonal and the nutritional contributions warrant assessment.

Does MARKABLE measure micronutrient status?

No. MARKABLE is a general wellness product, not a medical device. It does not measure vitamins, minerals or hormones and it does not diagnose, treat, or cure any condition. It produces a personal baseline across facial, cognitive, sensory and symptom signals that can be tracked over time and shared with a clinician.

References

Zimmermann MB, Köhrle J. The impact of iron and selenium deficiencies on iodine and thyroid metabolism: biochemistry and relevance to public health. Thyroid. 2002;12(10):867-878. doi:10.1089/105072502761016494
Uwitonze AM, Razzaque MS. Role of magnesium in vitamin D activation and function. Journal of the American Osteopathic Association. 2018;118(3):181-189. doi:10.7556/jaoa.2018.037
Prior JC, Hitchcock CL. The endocrinology of perimenopause: need for a paradigm shift. Frontiers in Bioscience (Scholar Edition). 2011;3(2):474-486. doi:10.2741/s166
Prior JC. Progesterone for the prevention and treatment of osteoporosis in women. Climacteric. 2018;21(4):366-374. doi:10.1080/13697137.2018.1467400
Wright VJ, Schwartzman JD, Itinoche R, Wittstein J. The musculoskeletal syndrome of menopause. Climacteric. 2024;27(5):466-472. doi:10.1080/13697137.2024.2380363

Sources were located and verified against PubMed. DOI links are provided so the primary literature can be read directly.

This article is educational content and does not constitute medical advice, diagnosis, or a recommendation to take any supplement. Iron supplementation without measurement may cause harm. MARKABLE is a general wellness product, not a medical device, and is not intended to diagnose, treat, cure, or prevent any disease.